Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Enzyte Marketers’ Prison Time Could Scare Firms Off Fraudulent Claims

This article was originally published in The Tan Sheet

Executive Summary

In a decision that will make executives think twice before taking part in making false claims and other deceptive behavior, an Ohio court sentenced 11 former employees of Berkeley Premium Nutraceuticals to prison for conspiracy, fraud and money laundering convictions related to marketing its Enzyte "natural male enhancement" product

You may also be interested in...



ProPhase Tries Direct-Response Supplement Sales As Remedy For Seasonal Slumps

The marketer of the Cold-EEZE cold remedy line enters the supplement market with LegendzXL "to offset the seasonality of our revenues and our dependence on the severity of the cold season." The supplement contains a proprietary formulation for "supporting physical readiness, energy and relieving stress."

FTC Provision In Finance Reform Bill Could Bite Supplement Firms

Dietary supplement trade groups join a wide swath of industries telling Congress a minor provision of extensive financial services reform legislation would give the Federal Trade Commission nearly unfettered rulemaking authority

FTC Provision In Finance Reform Bill Could Bite Supplement Firms

Dietary supplement trade groups join a wide swath of industries telling Congress a minor provision of extensive financial services reform legislation would give the Federal Trade Commission nearly unfettered rulemaking authority

Related Content

Topics

UsernamePublicRestriction

Register

PS102049

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel